ACI-7104.056
AC Immune Reports Promising Phase 2 Interim Data for Parkinson’s Immunotherapy ACI-7104.056
AC Immune; ACI-7104.056; Parkinson’s disease; Phase 2 trial; alpha-synuclein; biomarker stabilization
Actionable Insights Powered by AI
AC Immune; ACI-7104.056; Parkinson’s disease; Phase 2 trial; alpha-synuclein; biomarker stabilization